Japan's Chugai files to expand use of COVID-19 antibody drug
11/10/2021 09:11
TOKYO, Oct 11 (Reuters) - Japan's Chugai Pharmaceutical Co
4519.T said on Monday it has applied to regulators to expand
the use of an antibody treatment for COVID-19 to also allow for
preventative care.
Japanese regulators approved an antibody cocktail known as
Ronapreve as a treatment for COVID-19 in July. The latest filing
seeks to use the drug as both a prophylaxis for COVID-19 and as
treatment of asymptomatic cases, Chugai said in a release.
(Reporting by Rocky Swift, Editing by Timothy Heritage)
((rocky.swift@thomsonreuters.com;))
Recent news on Chugai Pharmaceutical
See all newsRegarding Discontinuation Of Development Of Gym329 (Emugrobart) For Obesity, Return Of License And Resumption Of Development For SMA
Table: Chugai Pharm 6-MTH group results (IFRS)
Japan's Nikkei roars past 62,000 on earnings, Middle East optimism; JGBs rally (updated)
Japan's Nikkei surges past 61,000 for first time on earnings, Mideast optimism
Japan's Nikkei closes above 60,000 for first time on earnings optimism (updated)